The All Party Committee on Environmental Objectives' expert group for Pharmaceuticals and Environmental issues met on Friday (Nov 11). It is a broadly assembled group, with representatives from all relevant stakeholders in society. This allows for very interesting and "energetic" discussions. Very stimulating! Friday's meeting included discussions on the balance between international actions and national ones. Which relevant proposals for new objectves, both global as well as national, within the area of "A Non-Toxic Environment" should the expert group provide to the All Party Committee? Not very surprsing, discussions of course included MPA's proposal on inclusion of environmental requirements into GMP, and also another MPA proposal from their report in Dec 2009, namely the use of Environmental Risk Assessments (ERAs) in the risk/benefit-evaluation in the authorization process for human medicines. But we also discussed green economic incentives within the pricing and reimbursement system which is being under review by Sofia Wallström presently. The All Party Committee cannot of course comment to much on the issue since it is being under review, but the issue should nevertheless not be left completely without comments. Another national topic discussed in the group is the potantial need for additional treatment steps in waste water treatment facilities. Such societal investments should not only be benefical for any pharmaceutical residues in the waste water but also for "chemicals of concern", e.g. endocrine disruptors.
It will be interesting to see how the discussions continue and over the coming months, and to see the final document from the All Party Commitee on Environmental Objectives on June 15, 2012.
Stay tuned for more information as the process continues.